Q3 2025 · 13F-HR
venBio Partners LLCholdings as filed
Filed 2025-11-14 · accession 0000905148-25-004034
$176.4M
Reported value
6
Positions
2025-09-30
Period end
The Brief · venBio Partners LLC · Q3 2025
AI · grounded in 13F
venBio Partners LLC established a new position in PHVS valued at $115.75M. The fund also initiated new stakes in ALMS for $18.43M and ALXO for $17.75M. Additional new positions include HRMY, LYEL, and ARTV.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N69605108 | PHVS | PHARVARIS N V | $115.8M | 65.6% | 4,639,304 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $18.4M | 10.4% | 4,619,803 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $17.8M | 10.1% | 9,699,925 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $13.5M | 7.64% | 489,194 | Common | SOLE |
| 55083R203 | LYEL | LYELL IMMUNOPHARMA INC | $7.7M | 4.36% | 473,479 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $3.3M | 1.87% | 1,148,975 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.